GRACE

cancergrace.org

 

GRACE
Avatar

Amivantamab/Lazertinib for EGFRm+ NSCLC Acquired Resistance

By GRACE FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
By GRACE FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
15 views
September 6, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam
ASCO Lung Review 2022
14:26
GRACE

The Need for Molecular Testing to Identify Targets in mNSCLC

Feat. J. West, J. Naidoo, G. Lopes
12:38
GRACE

IO Alone vs. IO + Chemo for NSCLC Pts w/PD-L1≥50%

Feat. J. West, J. Naidoo, G. Lopes
07:22
GRACE

Chemo/IO vs. IO vs. Chemo for KRAS-Mutated NSCLC

Feat. J. West, J. Naidoo, G. Lopes
07:37
GRACE

Pembrolizumab/Ramucirumab vs. Standard 2L Treatment After Chemo and …

Feat. J. West, J. Naidoo, G. Lopes
09:17
GRACE

Amivantamab/Lazertinib for EGFRm+ NSCLC Acquired Resistance

Feat. J. West, J. Naidoo, G. Lopes
07:11
GRACE

EGFRm+ NSCLC: Should We Treat With Durvalumab?

Feat. J. West, J. Naidoo, G. Lopes
05:29
GRACE

Patritumab Deruxtecan: Use in Previously Treated NSCLC Without Mutat…

Feat. J. West, J. Naidoo, G. Lopes
04:28
GRACE

SKYSCRAPER-2 Trial: Anti-“TIGIT” IO + Chemo/IO for ES-SCLC

Feat. J. West, J. Naidoo, G. Lopes
07:56
GRACE

CheckMate 816: Combining Chemo and Opdivo in Stage 1B-3A NSCLC

Feat. J. West, J. Naidoo, G. Lopes
12:08
GRACE

Adagrasib for Previously Treated KRAS G12C+ NSCLC

Feat. J. West, J. Naidoo, G. Lopes